Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | TERT | O14746 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL191244 | 1.00 | HPGD (0.46) | HPGDSMN1; SMN2LMNANPC1RAB9A | |
| Iodide SCHEMBL8481287 | 0.98 | HPGD (0.45) | HPGDSMN1; SMN2LMNANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL8478843 | 0.98 | HPGD (0.45) | HPGDSMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL30102368 | 0.86 | SMN1; SMN2 (0.42) | HPGDSMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL4505370 | 0.82 | HPGD (0.45) | HPGDSMN1; SMN2LMNAKDM4EHSD17B10 | |
| SCHEMBL8478862 | 0.82 | CYP2C19 (0.44) | HPGDSMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL10444586 | 0.78 | PDE3B (0.46) | HPGDSMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL28842567 | 0.78 | DAO (0.43) | HPGDSMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL8482426 | 0.78 | NPC1 (0.48) | SMN1; SMN2NPC1RAB9AKDM4EPKM | |
| SCHEMBL28242818 | 0.77 | HPGD (0.53) | HPGDSMN1; SMN2LMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408064-A1 | RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF | GENETOLEAD INC. (CA) | 2024-12-12 | — | — | US | disclosed |
| WO-2023060362-A1 | RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF | GENETOLEAD INC. (CA) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408064-A1 | RAS INHIBITORS, COMPOSITIONS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | HPGD 1297/4885SMN1; SMN2 3808/4885LMNA 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.